Study to Find Maintenance Dose for Periodic Administration of ASP3550
Astellas Pharma Inc · Prostatic Neoplasms
Phase 2
Completed
155
2024-10
Industry sponsor intelligence
Astellas Pharma IncClinical Pipeline.
Lead-sponsor view of Astellas Pharma Inc's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 9
- Recruiting
- 0
- Active
- 0
- Completed
- 9
- Results posted
- 0
- Avg enrollment
- 262
Pipeline overview
Programs by phase and activity.
Velocity
Astellas Pharma Inc trials by start year
Study start year · indexed snapshot
Development
Trials by phase
8phase labels
Early Phase 10
Phase 12
Phase 23
Phase 33
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Linaclotide → | 7 | 2 | 2 | 2 | 0 | 0 |
| Degarelix → | 2 | 0 | 1 | 1 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
Astellas Pharma Inc · Prostate Cancer
Phase 3
Completed
234
2024-10
A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
Astellas Pharma Inc · Constipation-predominant Irritable Bowel Syndrome (IBS-C)
Phase 2
Completed
559
2024-10
Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
Astellas Pharma Inc · Irritable Bowel Syndrome With Constipation (IBS-C)
Phase 3
Completed
500
2024-10
A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation
Astellas Pharma Inc · Chronic Constipation
Phase 2
Completed
383
2024-10
A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation
Astellas Pharma Inc · Chronic Constipation
Phase 3
Completed
186
2024-10
Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
Astellas Pharma Inc · Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases) · Irritable Bowel Syndrome With Constipation (IBS-C)
Not applicable
Completed
2,475
2024-10
A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy Subjects
Astellas Pharma Inc · Healthy · Pharmacokinetics of ASP0456
Phase 1
Completed
44
2011-09
A Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects
Astellas Pharma Inc · Healthy · Pharmacokinetics of ASP0456
Phase 1
Completed
32
2011-01
Search sponsor records
All Astellas Pharma Inc studies.
This page groups studies where Astellas Pharma Inc is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
9 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT01261572Study to Find Maintenance Dose for Periodic Administration of ASP3550Oct 31, 2024NCT01964170A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate CancerOct 31, 2024NCT01714843A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel SyndromeOct 18, 2024NCT02316899Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel SyndromeOct 18, 2024NCT02425722A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic ConstipationOct 18, 2024NCT02809105A Study of Oral Dosing of ASP0456 in Patients With Chronic ConstipationOct 18, 2024NCT03471728Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)Oct 18, 2024NCT01427387A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy SubjectsSep 23, 2011NCT01279915A Safety and Pharmacokinetics Study of ASP0456 in Healthy SubjectsJan 20, 2011